Physician

Dewey James Bailey, MD

According to 2025 Medicare claims, Dewey Bailey, MD (NPI: 1285628446) practices endocrinology in the Roanoke, VA market, with the plurality of this provider's patient population coming from Roanoke City, VA. This provider's primary affiliated billing organization is ENDOCRINOLOGY ASSOCIATES INC (NPI: 1275613473; TIN: 541915570) and primary practice location at 24018-3752.

Bailey's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,606 traditional Medicare patients, billed 34,607 HCPCS/CPT codes, and received $668,942 in Medicare payments. The top billing code was 84443 (Blood test, thyroid stimulating hormone (tsh)). Part D data shows 15,507 prescription claims across 1,690 beneficiaries totaling $6,174,769 in drug costs, led by Ozempic (Semaglutide). DME data shows 3,082 claims. Open Payments data shows 270 records totaling $60,685. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,572,456 to $6,174,769. For DME billing, reported payments moved sharply higher in recent years, from $69,573 to $840,527.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,473	92,400	$765,764
2016	1,541	112,071	$898,730
2017	1,627	104,728	$1,087,898
2018	1,721	101,512	$1,231,626
2019	1,681	71,313	$891,270
2020	1,551	31,868	$603,908
2021	1,371	32,760	$620,115
2022	1,273	30,963	$611,257
2023	1,629	35,291	$723,451
2024	1,606	34,607	$668,942

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	1,041	11,513	$2,572,456
2016	1,103	11,697	$2,802,818
2017	1,200	12,368	$3,474,475
2018	1,264	12,557	$3,888,439
2019	1,288	12,455	$4,165,445
2020	1,335	12,092	$4,512,215
2021	1,327	11,922	$5,053,056
2022	1,358	11,434	$5,222,170
2023	1,502	13,496	$6,912,874
2024	1,690	15,507	$6,174,769

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	1,338	3,124	$135,486
2016	1,320	3,117	$152,649
2017	1,055	2,229	$169,403
2018	1,058	2,679	$247,692
2019	1,056	3,006	$396,776
2020	874	2,957	$467,817
2021	801	3,267	$557,487
2022	739	3,477	$607,254
2023	779	3,772	$740,433
2024	754	3,082	$883,448

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
84443	Blood test, thyroid stimulating hormone (tsh)	1,286	2,620	$16
84439	Thyroxine (thyroid chemical), free	1,272	2,589	$9
36415	Insertion of needle into vein for collection of blood sample	1,315	2,855	$9
80048	Blood test, basic group of blood chemicals (calcium, total)	1,294	2,640	$8
80076	Liver function blood test panel	1,267	2,467	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	827	39,508	$1,270,129
Jardiance	Empagliflozin	569	31,581	$610,575
Tresiba Flextouch U-100	Insulin Degludec	515	37,461	$427,953
Tresiba Flextouch U-200	Insulin Degludec	203	12,795	$335,840
Farxiga	Dapagliflozin Propanediol	235	16,396	$302,035

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	368	2,125	$726,769
J1817	Insulin for administration through dme (i.e., insulin pump) per 50 units	N	30	95	$44,362
A4224	Supplies for maintenance of insulin infusion catheter, per week	N	55	157	$38,619
E0784	External ambulatory infusion pump, insulin	Y	17	92	$29,843
E2103	Non-adjunctive, non-implanted continuous glucose monitor or receiver	N	70	70	$14,366

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	270	$60,685	Novo Nordisk Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Dewey James Bailey, MD?

Tedicare shows public-source Medicare data for Dewey James Bailey, MD (NPI 1285628446), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Dewey James Bailey, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Dewey James Bailey, MD?

Dewey James Bailey, MD is linked to ENDOCRINOLOGY ASSOCIATES INC (billing NPI 1275613473) in the available physician profile data.

Does Dewey James Bailey, MD have Open Payments data?

Dewey James Bailey, MD has 270 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.